IL133303A0 - Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft - Google Patents

Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft

Info

Publication number
IL133303A0
IL133303A0 IL13330398A IL13330398A IL133303A0 IL 133303 A0 IL133303 A0 IL 133303A0 IL 13330398 A IL13330398 A IL 13330398A IL 13330398 A IL13330398 A IL 13330398A IL 133303 A0 IL133303 A0 IL 133303A0
Authority
IL
Israel
Prior art keywords
insulin
producing tissue
graft
compositions
tissue graft
Prior art date
Application number
IL13330398A
Other languages
English (en)
Original Assignee
Biogen Inc
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ Miami filed Critical Biogen Inc
Publication of IL133303A0 publication Critical patent/IL133303A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • External Artificial Organs (AREA)
  • Steroid Compounds (AREA)
IL13330398A 1997-06-20 1998-06-19 Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft IL133303A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US7726598P 1998-03-09 1998-03-09
PCT/US1998/012892 WO1998058669A2 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for pancreatic islet tissue transplantation

Publications (1)

Publication Number Publication Date
IL133303A0 true IL133303A0 (en) 2001-04-30

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13330398A IL133303A0 (en) 1997-06-20 1998-06-19 Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft

Country Status (22)

Country Link
US (2) US20030072754A1 (ru)
EP (1) EP1051191B1 (ru)
JP (1) JP2002506446A (ru)
KR (1) KR100634847B1 (ru)
CN (2) CN1195546C (ru)
AT (1) ATE339966T1 (ru)
AU (1) AU730763B2 (ru)
BG (1) BG64976B1 (ru)
BR (1) BR9810620A (ru)
CA (1) CA2294154A1 (ru)
DE (1) DE69835965T2 (ru)
EA (1) EA002550B1 (ru)
EE (1) EE9900588A (ru)
HK (1) HK1033548A1 (ru)
HU (1) HUP0003160A3 (ru)
IL (1) IL133303A0 (ru)
IS (1) IS5273A (ru)
NO (1) NO996275L (ru)
NZ (1) NZ502052A (ru)
SK (1) SK180299A3 (ru)
TR (1) TR199903142T2 (ru)
WO (1) WO1998058669A2 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
EP1289554A4 (en) * 2000-06-02 2004-05-26 Univ Minnesota IMMUNOTHERAPEUTIC PROCESS FOR PREVENTING REJECTION OF ISLAND CELLS
AU2001275411B2 (en) * 2000-06-09 2005-04-28 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
EP1814980B1 (en) * 2004-11-22 2015-03-25 Ramot at Tel-Aviv University Ltd. Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8911739B2 (en) 2009-02-10 2014-12-16 Trustees Of Columbia University In The City Of New York Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
BG64976B1 (bg) 2006-11-30
BR9810620A (pt) 2000-10-03
AU7983098A (en) 1999-01-04
WO1998058669A2 (en) 1998-12-30
HUP0003160A3 (en) 2002-09-30
NO996275D0 (no) 1999-12-17
US20070292440A1 (en) 2007-12-20
CN1195546C (zh) 2005-04-06
EP1051191B1 (en) 2006-09-20
EA002550B1 (ru) 2002-06-27
DE69835965D1 (de) 2006-11-02
JP2002506446A (ja) 2002-02-26
ATE339966T1 (de) 2006-10-15
US20030072754A1 (en) 2003-04-17
KR20010013965A (ko) 2001-02-26
KR100634847B1 (ko) 2006-10-17
WO1998058669A3 (en) 1999-04-29
DE69835965T2 (de) 2007-06-14
IS5273A (is) 1999-11-26
CN1261286A (zh) 2000-07-26
EP1051191A2 (en) 2000-11-15
NZ502052A (en) 2001-01-26
BG104091A (en) 2000-10-31
EA200000058A1 (ru) 2000-08-28
AU730763B2 (en) 2001-03-15
HK1033548A1 (en) 2001-09-07
CA2294154A1 (en) 1998-12-30
CN1651919A (zh) 2005-08-10
NO996275L (no) 2000-02-21
EE9900588A (et) 2000-08-15
HUP0003160A2 (hu) 2001-01-29
SK180299A3 (en) 2000-06-12
TR199903142T2 (xx) 2000-09-21

Similar Documents

Publication Publication Date Title
IL133303A0 (en) Use of a cd40: cd154 binding interruptor for inhibiting rejection of an insulin-producing tissue graft
CA2320040A1 (en) Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP1220611A4 (en) SUPPRESSOR CELLS FOR THE PREVENTION AND TREATMENT OF IMMUNE RESPONSES IN TRANSPLANTATIONS
ES2172533T3 (es) Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida.
HUP0003392A2 (hu) CD40:CD154 Kötés megszakításának alkalmazása beépülés elleni immunválaszok, különösen graft-kilökődés megakadályozására
Turcotte et al. Mechanisms of action of Mycobacterium bovis BCG-induced suppressor cells in mitogen-induced blastogenesis
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
PH30211A (en) Use of ifn-gamma for the treatment of infections in transplant recipients
IL95046A0 (en) Substituted 2-imidazolines and pharmaceutical compositions containing them
WO2003029432A3 (en) Human mesenchymal progenitor cell
EP1754490A3 (en) CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
EP0886528A4 (en) USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASES
AU6953296A (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
UA32295A (ru) Способ лечения нарушений фертильности у больных сахарным диабетом
JPS6485990A (en) Antihypertestoeronemia agent
AU641538B2 (en) Method for the preparation of sulphinyl pristinamycin IIB
JPS5765181A (en) Heat-resistant adenylate kinase and its preparation
Ambrogi et al. Effect of thymostimulin on human lymphocyte adenosine deaminase and purine nucleoside phosphorylase activities: physiological and therapeutic effects
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them
UA36081A (ru) Способ коррекции дисмикроэлементемии
UA38993A (ru) Инъекционный препарат маточного молочка пчел
UA39046A (ru) Способ лечения инсулинозависимого сахарного диабета
BG100540A (en) Nutritive for the isolation of kalfinella spp.